The company ElyssaMed is established at the end of 2015 with the support from l'Institut Gustave Roussy, coming as shareholder.
The company ElyssaMed is located now at the 1st Paris Bio-incubateur : Parisbiotech Santé, which is established at Cochin Hospital (APHP).
ElyssaMed® is a spin-off of Gustave Roussy Institute and will develop the first therapeutic treatment for clinical use comprising several antigenic peptides (epitopes) derived from CTPP and selective for non-small-cell lung cancer, combined with an already marketed vaccine adjuvant.
This product once administered to lung cancer patients, will amplify the patients' specific immune responses against tumor cells expressing the antigen CTPP and lead to their destruction.
Fathia MAMI-CHOUAIB, project director.
Research director at INSERM Normale, Fathia Mami-Chouaib obtained a PhD in immunology from the Pasteur Institute in Paris in 1984.
After a 3-year post-doctoral fellowship at NIH, Bethesda, USA, she was recruited to INSERM to continue her research at Gustave Roussy Institute.
Deposit of the 1st patent related to technology by the Institut Gustave Roussy, The university Paris SUD and INSERM.
Awards: Natioanal business creation and innovative technologies awardfrom the French Ministry of Education and Research.
ElyssaMed SAS was winner in the category "emerging companies".
